Tylent Insight

Welcome to the Lyvra Community Tech Blog

Human Factors Don’t Disappear: How Automation Still Depends on People (and Why That Matters)
Compounding Excellence Fabio Fioravanti Compounding Excellence Fabio Fioravanti

Human Factors Don’t Disappear: How Automation Still Depends on People (and Why That Matters)

i.v. compounding automation is often described as a way to remove the human factor. In reality, people remain deeply embedded in the workflow—preparing materials, loading components, resolving exceptions, and finishing products. The literature shows that these interactions frequently occur at the most fragile points of the process. Automation reduces handling, but system safety still depends heavily on human reliability.

Read More
The Serial Trap: Why Most i.v. Compounding Robots Hit a Performance Ceiling
Compounding Excellence Fabio Fioravanti Compounding Excellence Fabio Fioravanti

The Serial Trap: Why Most i.v. Compounding Robots Hit a Performance Ceiling

Across automated IV compounding platforms, a common design pattern emerges: a central workspace served by one or two robotic arms executing tasks sequentially. This architecture places a hard ceiling on scalability. As variability increases, serial workflows amplify delays, corrections, and waiting times. The result is a system that performs well in narrow scenarios but struggles to match the parallel nature of real pharmacy demand.

Read More
Semi-Finished Products, Persistent Risk: When Compounding Stops Too Early
Compounding Excellence Fabio Fioravanti Compounding Excellence Fabio Fioravanti

Semi-Finished Products, Persistent Risk: When Compounding Stops Too Early

IV compounding automation has made mixing safer and more consistent. But most systems still stop too early, delivering semi-finished products that require manual finishing before administration. Every additional handling step—spiking, connecting, priming—reopens the system to exposure and variability. Until automation closes the entire preparation loop, safety gains remain incomplete.

Read More
Needles, Coring, and Aerosols: Why Legacy Interfaces Still Drive Risk in IV Compounding
Compounding Excellence Fabio Fioravanti Compounding Excellence Fabio Fioravanti

Needles, Coring, and Aerosols: Why Legacy Interfaces Still Drive Risk in IV Compounding

Automation has improved many aspects of i.v. compounding, yet the interfaces connecting drugs to the system remain largely unchanged. Needles, spikes, and perforating access devices are still widely used across automated platforms. The literature shows that these interfaces can generate particulates, aerosols, and micro-leakage during routine operations. As automation scales, the risks associated with these legacy interfaces can become amplified rather than reduced.

Read More
Aseptic Technique Beyond the Buzzwords: “ISO 5” Is Not Enough
Compounding Excellence Fabio Fioravanti Compounding Excellence Fabio Fioravanti

Aseptic Technique Beyond the Buzzwords: “ISO 5” Is Not Enough

Automated compounding systems routinely meet sterility expectations, with negative media fills and successful microbiological validation. Yet the literature shows that aseptic risk is not eliminated—it is redistributed. Loading interfaces, non-sterile components, and airflow shadow zones introduce vulnerabilities that ISO 5 classification alone does not address. True aseptic robustness depends not only on room classification but on the continuity of first air and the design of the entire process.

Read More